Article

2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 58, n° 3
pages 382-386 (mars 2008)
Doi : 10.1016/j.jaad.2007.12.014
accepted : 16 December 2007
Reports

Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides
 

Putao Cen, MD a, Madeleine Duvic, MD b, c, Philip R. Cohen, MD b, c, d, Razelle Kurzrock, MD a,
a Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 
b Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 
c Department of Dermatology, University of Texas-Houston Medical School, Houston, Texas 
d University of Houston Health Center, Houston, Texas 

Reprint requests: Razelle Kurzrock, MD, Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, MD Anderson Cancer Center, Box 455, PO Box 301402, Houston, TX 77030.
Abstract
Background

Mycosis fungoides, also called cutaneous T-cell lymphoma, comprise a group of extranodal, indolent non-Hodgkin’s lymphomas of T-cell origin with primary involvement of the skin. There are few data available on tumor markers in these patients. Cancer antigen 27.29 (CA27.29), which is expressed on most carcinoma cells, is a soluble form of the glycoprotein MUC1. Measuring CA27.29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer.

Objective

We sought to assess whether CA27.29 levels were increased in patients with cutaneous T-cell lymphoma and whether there was a correlation of this marker with tumor response.

Methods

We evaluated the CA27.29 blood levels from 6 patients with advanced mycosis fungoides (who had no evidence of breast cancer) and reviewed their charts for information about history and physical examinations, laboratory data, pathology findings, and radiologic examinations.

Results

We demonstrated that 3 of 6 patients with advanced mycosis fungoides had markedly elevated CA27.29 blood levels. In the two patients who had serial blood levels drawn, CA27.29 increased or decreased during treatment as the disease progressed or responded, respectively.

Limitations

This study reflects pilot data on a limited number of patients.

Conclusions

Our observations suggest that CA27.29 merits further investigation as a tumor marker in patients who have cutaneous T-cell lymphoma.

The full text of this article is available in PDF format.

Abbreviations used : CA27.29, CHOP, CMED, CTCL, FDA, MF, sMUC1



 Supported in part by grant RR024148 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at www.ncrr.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from overview-translational.asp.
 Conflicts of interest: None declared.



© 2008  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline